If you or a loved one has advanced cancer and your oncologist has exhausted effective treatment options, consider joining this new clinical study that might offer a completely new set of treatments, along with test results indicating which of these new treatments are most likely to be effective for you.
The benefits this clinical study can offer you:
- Access to FDA-approved off-guideline cancer drugs, proven to be safe and effective for other cancer patients.
- Tailored treatment options based on diagnostic tests that determine which off-guideline drugs are most likely to be effective.
- No travel required: you will be treated by your oncologist at your regular cancer hospital.
Background
Cancer Commons has launched a clinical study (CCCS001 on www.clinicaltrials.gov) that enables advanced cancer patients who have exhausted effective treatments to access FDA-approved off-guideline drugs that are currently unavailable to them under the NCCN Guidelines.
Off-guideline drugs are FDA-approved cancer medications that are approved for certain types of cancer but not specifically for the patient's cancer type. For each type of cancer, the number of off-guideline drugs significantly surpasses the number of on-guideline drugs, offering a vast and untapped array of new treatment options for advanced cancer patients who have no remaining effective treatments.
To participate in the study, a patient must meet three requirements: (1) they must have a diagnostic test (genomic or DST) indicating that one or more off-guideline drugs might be effective for them, (2) they must have an oncologist willing to administer FDA-approved off-guideline drugs, and (3) they must be able to access the off-guideline drugs, either through their insurance or another method.
The study does not have designated sites. As the treating oncologist, you can administer treatment to the patient at your current hospital.
For more information, please visit www.cancercommons.org/CCCS001
